Cite
HARVARD Citation
Yang, Z. et al. (2021). Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer. EMBO molecular medicine. 13 (9), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Yang, Z. et al. (2021). Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer. EMBO molecular medicine. 13 (9), p. n/a. [Online].